Your browser doesn't support javascript.
loading
Pathogenic Variant Profile of Hereditary Cancer Syndromes in a Vietnamese Cohort.
Tran, Van Thuan; Nguyen, Sao Trung; Pham, Xuan Dung; Phan, Thanh Hai; Nguyen, Van Chu; Nguyen, Huu Thinh; Nguyen, Huu Phuc; Doan, Phuong Thao Thi; Le, Tuan Anh; Nguyen, Bao Toan; Jasmine, Thanh Xuan; Nguyen, Duy Sinh; Nguyen, Hong-Dang Luu; Nguyen, Ngoc Mai; Do, Duy Xuan; Tran, Vu Uyen; Nguyen, Hue Hanh Thi; Le, Minh Phong; Nguyen, Yen Nhi; Do, Thanh Thuy Thi; Truong, Dinh Kiet; Tang, Hung Sang; Phan, Minh-Duy; Nguyen, Hoai-Nghia; Giang, Hoa; Tu, Lan N.
Afiliación
  • Tran VT; Ministry of Health, Hanoi, Vietnam.
  • Nguyen ST; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Pham XD; Oncology Hospital, Ho Chi Minh City, Vietnam.
  • Phan TH; MEDIC Medical Center, Ho Chi Minh City, Vietnam.
  • Nguyen VC; Vietnam National Cancer Hospital, Hanoi, Vietnam.
  • Nguyen HT; University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Nguyen HP; University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Doan PTT; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Le TA; Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  • Nguyen BT; MEDIC Medical Center, Ho Chi Minh City, Vietnam.
  • Jasmine TX; MEDIC Medical Center, Ho Chi Minh City, Vietnam.
  • Nguyen DS; Department of Oncology, Faculty of Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
  • Nguyen HL; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Nguyen NM; Gene Solutions, Ho Chi Minh City, Vietnam.
  • Do DX; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Tran VU; Gene Solutions, Ho Chi Minh City, Vietnam.
  • Nguyen HHT; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Le MP; Gene Solutions, Ho Chi Minh City, Vietnam.
  • Nguyen YN; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Do TTT; Gene Solutions, Ho Chi Minh City, Vietnam.
  • Truong DK; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Tang HS; Gene Solutions, Ho Chi Minh City, Vietnam.
  • Phan MD; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Nguyen HN; Gene Solutions, Ho Chi Minh City, Vietnam.
  • Giang H; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
  • Tu LN; Gene Solutions, Ho Chi Minh City, Vietnam.
Front Oncol ; 11: 789659, 2021.
Article en En | MEDLINE | ID: mdl-35070997
BACKGROUND: Hereditary cancer syndromes (HCS) are responsible for 5-10% of cancer cases. Genetic testing to identify pathogenic variants associated with cancer predisposition has not been routinely available in Vietnam. Consequently, the prevalence and genetic landscape of HCS remain unknown. METHODS: 1165 Vietnamese individuals enrolled in genetic testing at our laboratory in 2020. We performed analysis of germline mutations in 17 high- and moderate- penetrance genes associated with HCS by next generation sequencing. RESULTS: A total of 41 pathogenic variants in 11 genes were detected in 3.2% individuals. The carrier frequency was 4.2% in people with family or personal history of cancer and 2.6% in those without history. The percentage of mutation carriers for hereditary colorectal cancer syndromes was 1.3% and for hereditary breast and ovarian cancer syndrome was 1.6%. BRCA1 and BRCA2 mutations were the most prevalent with the positive rate of 1.3% in the general cohort and 5.1% in breast or ovarian cancer patients. Most of BRCA1 mutations located at the BRCA C-terminus domains and the top recurrent mutation was NM_007294.3:c.5251C>T (p.Arg1751Ter). One novel variant NM_000038.6(APC):c.6665C>A (p.Pro2222His) was found in a breast cancer patient with a strong family history of cancer. A case study of hereditary cancer syndrome was illustrated to highlight the importance of genetic testing. CONCLUSION: This is the first largest analysis of carrier frequency and mutation spectrum of HCS in Vietnam. The findings demonstrate the clinical significance of multigene panel testing to identify carriers and their at-risk relatives for better cancer surveillance and management strategies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: Vietnam Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: Vietnam Pais de publicación: Suiza